Table 2.
General information of the 25 cancer patients whose fecal samples were analyzed
| Opioid-S (n = 10) | Opioid-T (n = 8) | Control (n = 7) | |
|---|---|---|---|
| Age, years | 61.20 ± 6.68 | 54.75 ± 11.60 | 59.71 ± 7.85 |
| Sex | |||
| Female | 0(0) | 3(37%) | 2(29%) |
| Male | 10(100%) | 5(63%) | 5(71%) |
| Cancer type | |||
| Lung cancer | 9(90%) | 8(100%) | 6(86%) |
| Esophageal cancer | 1(10%) | 0(0) | 1(14%) |
| Cancer staging | |||
| I | 0(0) | 0(0) | 1(14%) |
| II | 0(0) | 0(0) | 1(14%) |
| III | 2(20%) | 2(25%) | 1(14%) |
| IV | 8(80%) | 6(75%) | 4(57%) |
| ECOG | |||
| 0 | 3(30%) | 2(25%) | 3(43%) |
| 1 | 6(60%) | 4(50%) | 4(57%) |
| 2 | 1(10%) | 2(25%) | 0(0) |
| Body mass index (BMI, kg/m2) | 23.54 ± 3.41 | 21.25 ± 3.83 | 20.59 ± 1.91 |
| Total protein (g/l) | 66.41 ± 4.09 | 67.49 ± 4.94 | 71.09 ± 4.71 |
| Pain management | |||
| Oxycodone | 10(100%) | 8(100%) | NA |
| Dose (mg/day) | 21.00 ± 3.16 | 57.59 ± 19.23 | NA |
| Usage days | 14.00 ± 9.25 | 14.88 ± 7.49 | NA |
There were no significant differences in age, gender, tumor type and stage, ECOG score, BMI, and total protein in patients with moderate to severe cancer pain on opioids compared to the control group. Data are presented as the mean ± SD or n (%)
NA not applicable
Opioid-S: Opioid-sensitive group, regular administration of opioid for < 1 week or a daily total dose of < 30 mg oral oxycodone; Opioid-T: Opioid-tolerant group, took opioid medication regularly for at least 1 week, with a daily total dose of at least 30 mg of oral oxycodone; Control: Cancer patients without cancer pain